This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.
Current standard first-line treatment for advanced follicular lymphoma (FL) is still represented by chemoimmunotherapy combinations, with CHOP/CVP or bendamustine (B) as the main regimens with no standard criteria to prefer one over another. EZH2 mutations have been associated with longer progression-free survival (PFS) in patients treated with CHOP/CVP regimens, but not with Bendamustine (independently from the type of anti-CD20 therapy received). The FIL\_FOLL12 trial (NCT02063685), a large phase III trial (with a pre-planned biological material sampling) enrolling 807 advanced FL patients treated with front-line R-CHOP or bendamustine-rituximab (BR), appears an ideal platform to validate the predictive value of EZH2 and its applicability to the clinical practice. The aim of this study is to provide to clinicians a useful and practical biomarker to guide the choice of the most effective chemotherapy backbone (in addition to anti-CD20 immunotherapy) for first line treatment of patients with advanced FL (e.g. R-CHOP for EZH2 aberrated vs BR for EZH2 wild type patients). Moreover, to implement an Italian network of laboratories able to provide these translational outputs within a rapid turnaround time. Finally, taking advantage of the already collected BM and PB samples, several novel biomarkers of FL heterogeneity will be investigated, in particular: EZH2 protein expression in tumor samples, alternative molecular markers for minimal residual disease (MRD), clonal hematopoiesis of indeterminate potential (CHIP), pharmacogenomics and constitutional genomics as well as microbiome profiles.
Study Type
OBSERVATIONAL
Enrollment
654
Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
Progression free survival
Time between the treatment start and the first documentation of recurrence, progression or death from any cause
Time frame: From treatment start up to 43 months
Response rate
Response rate (complete metabolic response/minimal residual disease (MRD) negativity) at the end of induction.
Time frame: From treatment start to 7 months (R-Bendamustine) or from treatment start to 5,6 months (R-CHOP)
Concordance between EZH2 gene mutations/gains and EZH2-related gene expression signature
Concordance between EZH2 gene mutations/gains and EZH2-related gene expression signature
Time frame: Before treatment start
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia
Alessandria, Italy
RECRUITINGNuovo Ospedale degli Infermi, SSD Ematologia
Biella, Italy
RECRUITINGASST Spedali Civili di Brescia - Ematologia
Brescia, Italy
RECRUITINGAzienda Ospedaliera Universitaria Policlinico - S. Marco, UOC di Ematologia
Catania, Italy
RECRUITINGA.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
Cuneo, Italy
NOT_YET_RECRUITINGAzienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia
Florence, Italy
NOT_YET_RECRUITINGOspedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Ematologia e terapie cellulari
Genova, Italy
RECRUITINGIRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST S.R.L., Ematologia
Meldola, Italy
RECRUITINGASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
Milan, Italy
RECRUITINGFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Ematologia
Milan, Italy
RECRUITING...and 16 more locations